Combination of myeloproliferative and lymphoproliferative diseases: clinical observations

Currently, there is an increase in the number of publications, devoted to the problem of multiple primary tumors — neoplasms that occur simultaneously (synchronously) or alternately (metachronously), developing independently and independently of each other within the same or different organs. They are described as two, three or more nosologies. Due to the presence of defects in the immune system in chronic lymphocytic leukemia, solid tumors of different localization are a common finding. Their development is possible in other hematological diseases. This is probably due to success in the cure of tumor diseases, an increase in the life expectancy of patients, urbanization, an increase in the intensity of carcinogenic technogenic and medicinal effects, the presence of primary and secondary immunodeficiencies, as well as the use of modern diagnostic methods. Simultaneous detection of myeloproliferative and lymphoproliferative diseases in a patient is rare (in 1%), and this entails difficulties in diagnosing and prescribing therapy with such an association. In this regard, alertness is necessary in the presence of clinical and laboratory signs of a disease of the blood system that are not characteristic of the established type of hemoblastosis. And, of course, of undoubted interest is our own experience in managing such patients.

1. Меликян А.Л., Колошейнова Т.И., Горячева С.Р., Суборцева И.Н., Вахрушева М.В., Колосова Е.Н., и др. Синхронные и метахронные миелоидные и лимфоидные опухоли. Терапевтический архив. 2014;86(7):37-44.

2. Цыба Н.Н., Обухова Т.Н., Капланская И.Б., Ковалева Л.Г., Тихонова Л.Ю., Грецов Е.М., и др. Сочетание двух форм хронического лейкоза и солидной опухоли у одного больного. Терапевтический архив. 2007;79(10):74-77. eLIBRARY ID: 11626699

3. Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Bjorkholm M, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203-2210. doi: 10.1038/s41375-018-0027-y

4. Rumi E, Passamonti F, Elena C, Pietra D, Arcaini L, Astori C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96(3):454-8. doi: 10.3324/haematol.2010.033779.

5. Marchetti M, Carobbio A, Capitoni E, Barbui T. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. Am J Hematol. 2018;93(5):698-703. doi: 10.1002/ajh.25049

6. Hauck G, Jonigk D, Kreipe H, Hussein K. Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms. Acta Haematol. 2013;129(3):187-96. doi: 10.1159/000342484

7. Hussein K, Brakensiek K, Ballmaier M, Bormann M, Gohring G, Buhr T, et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol. 2006;77(6):539-41. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2940.x

8. Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86(12):1007-12. doi: 10.1002/ajh.22171

9. Vannucchi AM, Masala G, Antonioli E, Chiara Susini M, Guglielmelli P, Pieri L, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2068-73. doi: 10.1158/1055-9965.EPI-09-0353

10. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, S0rensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515-20. doi: 10.1182/blood-2011-04-348755